XNASENTX
Market cap79mUSD
Dec 26, Last price
2.15USD
1D
-1.15%
1Q
6.97%
IPO
-65.87%
Name
Entera Bio Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
29.44%
Rev. gr., 5y
-6.36%
Revenues
0k
-100.00%
Net income
-9m
L-31.99%
CFO
-7m
L-41.52%
Earnings
Mar 06, 2025
Profile
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 134 -76.53% | 571 56.44% | |||||||
Cost of revenue | 8,996 | 13,202 | 12,834 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (8,996) | (13,068) | (12,263) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 29 | 137 | (59) | ||||||
Tax Rate | |||||||||
NOPAT | (9,025) | (13,205) | (12,204) | ||||||
Net income | (8,889) -31.99% | (13,071) 7.25% | (12,187) 22.08% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 6,616 | 13 | 25,381 | ||||||
BB yield | -38.01% | -0.06% | -34.50% | ||||||
| Debt | |||||||||
Debt current | 268 | 91 | 179 | ||||||
Long-term debt | 902 | 91 | 425 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | (224) | 32 | 138 | ||||||
Net debt | (9,849) | (12,127) | (24,288) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (7,310) | (12,499) | (9,063) | ||||||
CAPEX | (17) | (47) | (17) | ||||||
Cash from investing activities | (17) | (102) | (17) | ||||||
Cash from financing activities | 6,036 | 13 | 25,381 | ||||||
FCF | (9,374) | (12,949) | (12,407) | ||||||
| Balance | |||||||||
Cash | 11,019 | 12,309 | 24,892 | ||||||
Long term investments | |||||||||
Excess cash | 11,019 | 12,302 | 24,863 | ||||||
Stockholders' equity | (104,344) | (95,456) | (82,385) | ||||||
Invested Capital | 115,286 | 107,333 | 105,256 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 29,008 | 28,808 | 26,134 | ||||||
Price | 0.60 -17.81% | 0.73 -74.07% | 2.82 160.65% | ||||||
Market cap | 17,405 -17.24% | 21,030 -71.41% | 73,567 269.86% | ||||||
EV | 7,556 | 8,903 | 49,279 | ||||||
EBITDA | (8,940) | (13,004) | (12,210) | ||||||
EV/EBITDA | |||||||||
Interest | 26,002 | 29 | |||||||
Interest/NOPBT | |||||||||